Literature DB >> 21459613

Challenging the surgical rodent hindlimb ischemia model with the miniinterventional technique.

Zhen W Zhuang1, Jing Shi, John M Rhodes, Michael J Tsapakos, Michael Simons.   

Abstract

PURPOSE: To develop an interventional hindlimb ischemic model and compare its angiogenic effect versus surgical ligation (SL) and excision of the femoral artery in rats treated with transplantation of bone marrow mononuclear cells (MNCs) as an angiogenic stimulator.
MATERIALS AND METHODS: Forty-eight Lewis rats randomly received interventional embolization (IE) with hydrogel wire or SL and excision of the right femoral artery. Rodents were intraarterially transplanted with 1.5 × 10(7) MNCs in 500 μL medium from 24 isogenic donor rats. Functional and structural recovery was evaluated by laser Doppler imaging (LDI), cytokine/chemokine assay, and histologic staining.
RESULTS: In vivo microscopic images showed significantly dilated vasa vasorum around the embolized segment of the right femoral artery at 3 days compared with disorganized tissue structure in the SL group. However, the LDI index was significantly higher in the SL group at 3 days compared with the IE group. LDI did not significantly differ between the two groups at 2 weeks after transplantation. Cytokine assay showed higher levels of interleukin (IL)-1α and IL-18 in the SL group; the IE group had higher levels of interferon-γ, IL-6, IL-13, and granulocyte colony-stimulating factor. Histologic examination demonstrated inflammatory infiltration near the incision within nerve fibers with dilated capillaries, showing nerve degeneration in the SL group. At 2 weeks, histologic analysis demonstrated massive scarring under the skin spreading into the musculature in the SL group.
CONCLUSIONS: A minimally invasive hindlimb ischemia model has been successfully developed that preserves tissue integrity and minimizes inflammation and confounding factors in the early stages of angiogenesis and arteriogenesis.
Copyright © 2011 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21459613      PMCID: PMC3367666          DOI: 10.1016/j.jvir.2010.12.039

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  35 in total

Review 1.  Therapeutic angiogenesis: protein and gene therapy delivery strategies.

Authors:  T K Rosengart; S R Patel; R G Crystal
Journal:  J Cardiovasc Risk       Date:  1999-02

Review 2.  Therapeutic angiogenesis in cardiovascular disease.

Authors:  Michael Simons; J Anthony Ware
Journal:  Nat Rev Drug Discov       Date:  2003-11       Impact factor: 84.694

3.  Time course of skeletal muscle repair and gene expression following acute hind limb ischemia in mice.

Authors:  Nicholas F Paoni; Franklin Peale; Fay Wang; Carol Errett-Baroncini; Hope Steinmetz; Karen Toy; Wei Bai; P Mickey Williams; Stuart Bunting; Mary E Gerritsen; Lyn Powell-Braxton
Journal:  Physiol Genomics       Date:  2002-12-03       Impact factor: 3.107

4.  Participation of angiogenesis from rat femoral veins in the neovascularization of adjacent occluded arteries.

Authors:  J F Madrid; L Díaz-Flores; R Gutiérrez; H Varela; F Valladares; N Rancel; F Rodríguez
Journal:  Histol Histopathol       Date:  1998-01       Impact factor: 2.303

Review 5.  The biology of vascular endothelial growth factor.

Authors:  N Ferrara; T Davis-Smyth
Journal:  Endocr Rev       Date:  1997-02       Impact factor: 19.871

6.  Actions of TNF and IFN-gamma on angiogenesis in vitro.

Authors:  N Sato; H Nariuchi; N Tsuruoka; T Nishihara; J G Beitz; P Calabresi; A R Frackelton
Journal:  J Invest Dermatol       Date:  1990-12       Impact factor: 8.551

Review 7.  Preclinical models of human peripheral arterial occlusive disease: implications for investigation of therapeutic agents.

Authors:  Richard E Waters; Ronald L Terjung; Kevin G Peters; Brian H Annex
Journal:  J Appl Physiol (1985)       Date:  2004-04-23

8.  Angiogenesis-dependent and independent phases of intimal hyperplasia.

Authors:  Rohit Khurana; Zhenwu Zhuang; Shalini Bhardwaj; Masahiro Murakami; Ebo De Muinck; Seppo Yla-Herttuala; Napoleone Ferrara; John F Martin; Ian Zachary; Michael Simons
Journal:  Circulation       Date:  2004-10-11       Impact factor: 29.690

9.  The prevalence of peripheral arterial disease in a defined population.

Authors:  M H Criqui; A Fronek; E Barrett-Connor; M R Klauber; S Gabriel; D Goodman
Journal:  Circulation       Date:  1985-03       Impact factor: 29.690

10.  Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).

Authors:  Ronnier J Aviles; Brian H Annex; Robert J Lederman
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

View more
  4 in total

1.  A mitochondrial contribution to anti-inflammatory shear stress signaling in vascular endothelial cells.

Authors:  Brian G Coon; Sushma Timalsina; Matteo Astone; Zhen W Zhuang; Jennifer Fang; Jinah Han; Jurgen Themen; Minhwan Chung; Young Joo Yang-Klingler; Mukesh Jain; Karen K Hirschi; Ai Yamamato; Louis-Eric Trudeau; Massimo Santoro; Martin A Schwartz
Journal:  J Cell Biol       Date:  2022-06-13       Impact factor: 8.077

2.  Recovery of limb perfusion and function after hindlimb ischemia is impaired by arterial calcification.

Authors:  Sara L Zettervall; Xue-Lin Wang; Stephanie Monk; Tonghui Lin; Yujun Cai; Raul J Guzman
Journal:  Physiol Rep       Date:  2021-08

3.  Rat model of hindlimb ischemia induced via embolization with polyvinyl alcohol and N-butyl cyanoacrylate.

Authors:  Cheong-Il Shin; Hyo-Cheol Kim; Yong Sub Song; Hye Rim Cho; Kyoung-Bun Lee; Whal Lee; Hwan Jun Jae; Jin Wook Chung
Journal:  Korean J Radiol       Date:  2013-11-05       Impact factor: 3.500

4.  Regenerative Potential of the Product "CardioCell" Derived from the Wharton's Jelly Mesenchymal Stem Cells for Treating Hindlimb Ischemia.

Authors:  Aleksandra Musiał-Wysocka; Marta Kot; Maciej Sułkowski; Marcin Majka
Journal:  Int J Mol Sci       Date:  2019-09-18       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.